Of interest, and in line with our observations, high expression of MVA pathway genes e.g., HMGCR, has been reported to be associated with resistance to therapeutic targeting of the MVA pathway and with poor patient prognosis in breast cancer [18, 22]. This evidence concerns the gene HMGCR and breast carcinoma.